Phase II Optimization, Open-Label Clinical Trial of Zalypsis® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients

被引：0
|
作者：
Ocio, Enrique M. [1 ]
De La Rubia, Javier [2 ]
Oriol-Rocafiguera, Albert [3 ]
Blade, Joan [4 ]
Rodriguez, Jose [5 ]
Coronado, Cinthya [5 ]
Martin Sanchez, Jesus [6 ]
Isabel Teruel, Ana [7 ]
Hernandez-Maraver, Dolores [8 ]
Prosper, Felipe [9 ]
San-Miguel, Jesus. F.
机构：
[1] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain
[2] Hosp Univ La Fe, Valencia, Spain
[3] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] PharmaMar, Madrid, Spain
[6] Hosp Univ Virgen del Rocio, Seville, Spain
[7] Hosp Clin Univ Valencia, Valencia, Spain
[8] Hosp La Paz, Madrid, Spain
[9] Univ Navarra Clin, Pamplona, Spain
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4041.4041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4041
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma
    Ocio, Enrique M.
    Oriol, Albert
    Blade, Joan
    Teruel, Ana I.
    Martin, Jesus
    de la Rubia, Javier
    Gutierrez, Norma C.
    Rodriguez Diaz-Pavon, Jose
    Martinez Gonzalez, Sara
    Coronado, Cinthya
    Fernandez-Garcia, Eva M.
    Siguero Gomez, Mariano
    Fernandez-Teruel, Carlos
    San Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (04) : 625 - 628
  • [2] A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors
    Robin L. Jones
    Stefano Ferrari
    Jean Yves Blay
    Fariba Navid
    Pilar Lardelli
    Vicente Alfaro
    Mariano Siguero
    Neelesh Soman
    Sant P. Chawla
    Investigational New Drugs, 2014, 32 : 171 - 177
  • [3] A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors
    Jones, Robin L.
    Ferrari, Stefano
    Blay, Jean Yves
    Navid, Fariba
    Lardelli, Pilar
    Alfaro, Vicente
    Siguero, Mariano
    Soman, Neelesh
    Chawla, Sant P.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 171 - 177
  • [4] Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen
    Daniel E. Castellano
    Joaquim Bellmunt
    José Pablo Maroto
    Albert Font-Pous
    Rafael Morales-Barrera
    Ismael Ghanem
    Cristina Suarez
    Cristina Martín Lorente
    Olatz Etxaniz
    Laia Capdevila
    Cinthya Coronado
    Vicente Alfaro
    Mariano Siguero
    Carlos Fernández-Teruel
    Joan Carles
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 857 - 867
  • [5] An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Yellin, Ori
    Bessudo, Alberto
    Boccia, Ralph
    Gravenor, Donald S.
    Noga, Stephen
    Siegel, Robert S.
    Swift, Regina A.
    Ehrman, Michael D.
    Bensen-Kennedy, Debra
    BLOOD, 2010, 116 (21) : 1261 - 1261
  • [6] Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors
    Ramón Salazar
    Antonio Calles
    Marta Gil
    Ignacio Durán
    Margarita García
    Manuel Hidalgo
    Cinthya Coronado
    Vicente Alfaro
    Mariano Siguero
    Carlos Fernández-Teruel
    Raquel Prados
    Emiliano Calvo
    Investigational New Drugs, 2014, 32 : 644 - 652
  • [7] Recombinant Circularly Permuted TRAIL (CPT) for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial
    Chen, Wenming
    Qiu, Lugui
    Hou, Jian
    Zhao, Yaozhong
    Pan, Ling
    Yang, Shifang
    Leng, Yun
    Xi, Hao
    Zhang, Xuejun
    Cui, Junsheng
    Wei, Na
    BLOOD, 2012, 120 (21)
  • [8] A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
    Stakiw, Julie
    Kodad, Shruthi
    LeBlanc, Richard
    Sebag, Michael
    Hay, Annette E.
    Kukreti, Vishal
    Cote, Julie
    Camacho, Fernando
    Fu, Molei
    Gul, Engin
    Reece, Donna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 484 - 490
  • [9] Phase II study of weekly PM00104 (ZALYPSIS®) in patients with pretreated advanced/metastatic endometrial or cervical cancer
    Martin, Lainie P.
    Krasner, Carolyn
    Rutledge, Teresa
    Luque Ibanes, Manuel
    Fernandez-Garcia, Eva M.
    Kahatt, Carmen
    Siguero Gomez, Mariano
    McMeekin, Scott
    MEDICAL ONCOLOGY, 2013, 30 (03)
  • [10] Phase II study of weekly PM00104 (ZALYPSIS®) in patients with pretreated advanced/metastatic endometrial or cervical cancer
    Lainie P. Martin
    Carolyn Krasner
    Teresa Rutledge
    Manuel Luque Ibañes
    Eva M. Fernández-García
    Carmen Kahatt
    Mariano Siguero Gómez
    Scott McMeekin
    Medical Oncology, 2013, 30
12345